Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Observational, Non-interventional Study to Evaluate the Safety and Efficacy of Anti-TNF (Anti-Tumor Necrosis Factor) Alpha Therapy With Certolizumab Pegol Observed in Daily Practice in Adult Rheumatoid Arthritis (RA) Patients

NCT01069419 is registered in ClinicalTrials.gov with UCB Pharma GmbH as lead sponsor.

NCT NCT01069419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01069419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Observational, Non-interventional Study to Evaluate the Safety and Efficacy of Anti-TNF (Anti-Tumor Necrosis Factor) Alpha Therapy With Certolizumab Pegol Observed in Daily Practice in Adult Rheumatoid Arthritis (RA) Patients
Lead sponsor
UCB Pharma GmbH
Phase
Observational
Overall status
Completed
Start date
October 31, 2009
Completion date
December 31, 2014
Enrollment
1,117 (actual)
Sites
163

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis